Drug & intervention

gedatolisib

RxCUI 2747771

Clinical trials10
Recruiting1
Related conditions16
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

10 shown
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate CancerNCT06190899 · 2024-01-01
RECRUITING
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)NCT05501886 · 2022-12-08
ACTIVE_NOT_RECRUITING
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersNCT03911973 · 2019-04-17
ACTIVE_NOT_RECRUITING
Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")NCT03400254 · 2019-02-26
WITHDRAWN
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast CancerNCT03243331 · 2018-01-19
COMPLETED
Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)NCT02920450 · 2017-09-25
TERMINATED
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsNCT03065062 · 2017-02-28
SUSPENDED
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast CancerNCT02684032 · 2016-06-14
COMPLETED
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast CancerNCT02626507 · 2016-01-01
UNKNOWN
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009NCT05134922
AVAILABLE

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.